Ryan Johnson | White & Case LLP International Law Firm, Global Law Practice
 Ryan Johnson
 Ryan Johnson

Ryan Johnson

Associate, New York

T +1 212 819 8893

E rjohnson@whitecase.com

Overview

Ryan Johnson represents clients in complex intellectual property litigation. He has extensive experience trying pharmaceutical patent infringement cases arising under the Hatch-Waxman act. He also represents pharmaceutical companies in antitrust actions arising out of prior patent cases.

Mr. Johnson has also represented clients in the consumer products, telecommunications, and high-tech industries in patent infringement matters. He also advises clients on the intellectual property-related aspects of acquisitions and other transactions.

Mr. Johnson's undergraduate degree is in Biotechnology. Before attending law school, he researched experimental recombinant DNA vaccines for the HIV virus. He also spent several years working for a leading consumer products company as a product formulator and process development engineer.

Bars and Courts

  • Connecticut State Bar
  • New York State Bar
  • US Court of Appeals for the Federal Circuit
  • US District Court for the Eastern District of New York
  • US District Court for the Southern District of New York

Education

  • JD, University of Connecticut School of Law
  • BS, Biotechnology, Worcester Polytechnic Institute

Languages

  • English

Experience

Represented Pfizer Inc. and UCB Pharma GmbH at trial in a patent infringement case against five generic manufacturers concerning Toviaz®. The US District Court for the District of Delaware ruled in our clients' favor on all issues.  Pfizer Inc. v. Sandoz Inc., No. 13-1110-GMS, 2016 WL 1611377 (D. Del. Apr. 20, 2016).

Represented Pfizer Inc. and UCB Pharma GmbH in a second patent infringement trial concerning Toviaz®.  At the close of evidence, the Court issued a general verdict from the bench in favor of our clients all issues.  Pfizer Inc. v. Mylan Pharms. Inc., No. 15-0079-GMS (D. Del. Jan. 26, 2017).

Represented Pfizer at trial in a patent infringement case against eight generic manufacturers concerning Lyrica®.  The US District Court for the District of Delaware ruled in Pfizer's favor on all issues. Pfizer Inc. v. Teva Pharms. USA, Inc., 882 F. Supp. 2d 643 (D. Del. 2012), aff'd 555 Fed. Appx. 961 (2014).

Represented Pfizer at trial in a patent infringement case concerning Detrol® and Detrol® LA.  The US District Court for the District of New Jersey ruled in Pfizer's favor on all issues. Pfizer Inc. v. IVAX Pharms., Inc., 2010 WL 339042 (D.N.J. Jan. 20, 2010).

Represented Pfizer in a series of cases concerning controlled release formulation patents covering Detrol® LA. The cases settled favorably for Pfizer after the US District Court for the District of New Jersey ruled in Pfizer's favor on every disputed claim construction issue. Pfizer Inc. v. Teva Pharmaceuticals USA, Inc., 855 F. Supp. 2d 286 (D.N.J. 2012).

Representing a major pharmaceutical company in Inter Partes Review (IPR) proceedings concerning PEGylation of therapeutic proteins.

Representing a major pharmaceutical company in Inter Partes Review (IPR) proceedings concerning nanofiltration of recombinant protein compositions.

Representing Altergon SA, IBSA Institut Biochemique, and Teikoku Seiyaku Co. in pending patent infringement litigation concerning the drug Flector®.  Altergon SA v. Actavis Labs. UT, Inc., No. 15-883-RGA (D. Del.).

Representing Pfizer in a class action lawsuit concerning the drug Celebrex® arising under federal and state antitrust and unfair competition laws.  In re Celebrex Antitrust Litigation, Nos. 14-361 & 14-395 (E.D. Va.).

Represented foreign wireless telecommunications carriers as defendants in a patent infringement action involving over 130 parties. The US District Court for the District of Maryland granted our motion to dismiss the foreign carriers for lack of personal jurisdiction, and the Federal Circuit affirmed. Technology Patents, LLC v. Deutsche Telekom AG, 573 F. Supp. 2d 903 (D. Md. 2008).

Publications